Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Zacks.com featured highlights include: Insight, ConocoPhillips, Vale, Alexion and Archer Daniels

Zacks.com featured highlights include: Insight, ConocoPhillips, Vale, Alexion and Archer Daniels

    5 Stocks Trading Near 52-Week High With More Upside in Store

    Here are some stocks trading near their 52-week high levels with potential to scale higher.

      Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up

      ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.

        Alexion (ALXN) Tops Q2 Earnings and Revenues Beat Estimates

        Alexion beat both earnings and sales estimates in the second quarter of 2018.

          Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates

          Alexion (ALXN) delivered earnings and revenue surprises of 22.49% and 6.55%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

            Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More

            Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.

              Is a Beat in Store for Alexion (ALXN) This Earnings Season?

              Alexion is likely to provide details about the pipeline portfolio when it reports its second-quarter 2018 results on Jul 26.

                Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?

                While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

                  ALXN or RGNX: Which Is the Better Value Stock Right Now?

                  ALXN vs. RGNX: Which Stock Is the Better Value Option?

                    ALXN vs. RGNX: Which Stock Is the Better Value Option?

                    ALXN vs. RGNX: Which Stock Is the Better Value Option?

                      Karyopharm Initiates NDA Submission Process for Selinexor

                      Karyopharm Therapeutics (KPTI) initiates rolling submission of a New Drug Application to the FDA with a request for accelerated approval for selinexor.

                        J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)

                        A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

                          J&J's (JNJ) Phase III Study for Invokana Halted Earlier

                          Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.

                            J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales

                            J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.

                              J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)

                              A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

                                Roche's Flu Drug Meets Primary Endpoint in Phase III Study

                                Roche (RHHBY) announces that its antiviral candidate, baloxavir marboxil, met the primary endpoint in a phase III study in patients suffering from risk of complications from the flu.

                                  Alexion Pharmaceuticals (ALXN): Moving Average Crossover Alert

                                  Alexion Pharmaceuticals, Inc. (ALXN) is looking like an interesting pick from a technical perspective

                                    Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population

                                    FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

                                      Achillion's 3rd Factor D Inhibitor Enters Clinical Studies

                                      Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor.

                                        ALXN vs. RGNX: Which Stock Should Value Investors Buy Now?

                                        ALXN vs. RGNX: Which Stock Is the Better Value Option?

                                          Alexion (ALXN) Submits Application for ALXN1210 with FDA

                                          Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).

                                            Sweta Killa headshot

                                            Sarepta Pharma Pushes Two Biotech ETFs to New Highs

                                            The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.

                                              Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash

                                              The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.

                                                Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

                                                Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

                                                  Alexion-Complement Pharma Tie Up to Treat Neuro Disorders

                                                  Alexion (ALXN) teams up with Complement Pharma to co-develop its C6 inhibitor, CP010, for neurodegenerative disorders.